Galen Partners: A Leading US Biotech Investment and Acquisition Firm

Galen Partners is a well-established US biotech investment and acquisition firm. They have a proven track record of success in the industry.

Founded in 1994, Galen Partners has over 25 years of experience in investing in and acquiring biotech companies. Their extensive knowledge and expertise have allowed them to navigate the complex biotech landscape.

Galen Partners has a strong focus on identifying and investing in companies with innovative technologies and products.

Galen Partners is a private equity firm that focuses on investing in healthcare companies. They have a team of experienced professionals who work together to identify and invest in promising businesses.

Their investment approach is centered around partnering with talented entrepreneurs and management teams to drive growth and innovation. They take a hands-on approach to help their portfolio companies succeed.

Galen Partners has a long history of investing in the healthcare industry, with a focus on medical devices, healthcare services, and pharmaceuticals. They have a strong track record of delivering returns for their investors.

Their team has a deep understanding of the healthcare industry and its various segments, which enables them to make informed investment decisions. They also have a network of relationships with key stakeholders in the industry.

Galen Partners has a diverse portfolio of investments across various industries.

Their investment focus areas include business services, consumer products, healthcare, and industrial manufacturing.

Galen Partners has invested in over 100 companies, with a total committed capital of over $1.5 billion.

Their portfolio companies have experienced significant growth, with many achieving returns of 3-5 times their initial investment.

Galen Partners' investment approach emphasizes long-term value creation, often taking a minority stake in companies to allow for continued growth and development.

Their experienced investment team conducts thorough due diligence to identify promising investment opportunities.

By partnering with talented entrepreneurs and management teams, Galen Partners helps drive growth and innovation in their portfolio companies.

Galen Partners has been making waves in the industry with its latest news and acquisitions. Philip Borden, a seasoned venture capitalist, has taken a majority stake in the shared lab space company, teaming up with private equity firm Pacific Lake Partners to expand operations through Greater Boston.

Galen Partners has also been actively acquiring companies, with two notable acquisitions under its belt. Its latest acquisition was Evolve Treatment Centers in January 2020, a deal that was reportedly worth $XXM.

Here's a breakdown of Galen Partners' acquisitions:

Galen Partners has a history of investing in promising companies, and its latest acquisition is a testament to its commitment to growth and expansion.

Galen Partners has a significant track record of successful portfolio exits, with 22 exits in total.

Their latest portfolio exit was Life Image, which was acquired by Intelerad Medical Systems on September 15, 2022, for an undisclosed valuation of $XXM.

Sharecare was another notable exit, which occurred through a reverse merger with Falcon Capital Acquisition on July 1, 2021, also for a valuation of $XXM.

PeriGen was acquired by Halma on April 27, 2021, for $XXM.

Here are the details of Galen Partners' portfolio exits:

Galen Partners has made significant investments in various companies. Their latest acquisition was Evolve Treatment Centers in January 2020, with a valuation of $XXM.

Galen Partners acquired Evolve Treatment Centers in January 2020, marking one of their recent deals. The exact valuation of the acquisition is not publicly disclosed.

Galen Partners has also made investments in other companies, including one in 2003. The investment stage for this deal was Series A.

Here is a list of Galen Partners' acquisitions: